SCHEMBL234542

SCHEMBL234542

C=CC(F)(F)P(=O)(O)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1533911 0.73
SCHEMBL3890237 0.72 PGK1 (0.36)
SCHEMBL2459230 0.69 LMNA (0.33)
SCHEMBL777454 0.67 PGK1 (0.32)
SCHEMBL2814420 0.67 LMNA (0.38)
SCHEMBL641074 0.66
SCHEMBL2000403 0.65 FDPS (0.30)
SCHEMBL777401 0.65 PGK1 (0.40)
SCHEMBL28491843 0.65
Phosphoric Acid SCHEMBL28521742 0.65 PGK1 (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2481743-B1 LPA receptor agonists and antagonists and methods of use UNIV TENNESSEE RES FOUND (US) 2017-03-22 EP disclosed
EP-2433946-B1 LPA receptor agonists and antagonists and methods of use UNIV TENNESSEE RES FOUNDATION (US) 2016-04-20 EP disclosed
EP-2481743-A1 LPA receptor agonists and antagonists and methods of use UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2012-08-01 EP disclosed
US-20120135967-A1 LPA RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF USE MILLER DUANE D (US) 2012-05-31 US disclosed
EP-2433946-A1 LPA receptor agonists and antagonists and methods of use University of Tennessee Research Foundation (US) 2012-03-28 EP disclosed
EP-1678096-B1 LPA RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF USE UNIV TENNESSEE RES FOUNDATION (US) 2012-01-04 EP disclosed
US-7947665-B2 lysophosphatidic acid receptor modulator; thiophosphoric acid O-[7-(4-octyl-phenyl)-heptyl] ester; treating cancer, wounds, skin disorders and apoptosis; preserving or restoring function in a cell, tissue or organ; culturing cells; preserving organ or tissue function; and enhancing cell proliferation MILLER DUANE D 2011-05-24 US disclosed
US-20080090783-A1 lysophosphatidic acid receptor modulator; thiophosphoric acid O-[7-(4-octyl-phenyl)-heptyl] ester; treating cancer, wounds, skin disorders and apoptosis; preserving or restoring function in a cell, tissue or organ; culturing cells; preserving organ or tissue function; and enhancing cell proliferation MILLER DUANE D 2008-04-17 US disclosed
US-7217704-B2 LPA receptor agonists and antagonists and methods of use THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2007-05-15 US disclosed
EP-1678096-A4 LPA RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF USE UNIV TENNESSEE RES CORP (US) 2007-04-18 EP disclosed
EP-1678096-A2 LPA RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF USE THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) 2006-07-12 EP disclosed
US-20060009507-A1 Thio-phosphoric and -phosphorous acid derivatives; treating cancer, wounds, skin disorders and apoptosis; preserving or restoring function in a cell, tissue or organ; culturing cells; preserving organ or tissue function; and enhancing cell proliferation UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2006-01-12 US disclosed
WO-2005032494-A2 LPA RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF USE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2005-04-14 WO disclosed
EP-1502950-A2 Method for purifying chemically modified RNA RIBOZYME PHARMACEUTICALS, INC. (US) 2005-02-02 EP disclosed
EP-1260586-A2 Method and reagent for inhibiting the expression of disease related genes RIBOZYME PHARMACEUTICALS, INC. (US) 2002-11-27 EP disclosed
JP-2002080485-A NEW NORBORNENE ANALOGOUS COMPOUND HISAMITSU PHARMACEUT CO INC 2002-03-19 JP disclosed
EP-0746614-A1 METHOD AND REAGENT FOR INHIBITING THE EXPRESSION OF DISEASE RELATED GENES RIBOZYME PHARMACEUTICALS, INC. (US) 1996-12-11 EP disclosed
WO-1995023225-A2 METHOD AND REAGENT FOR INHIBITING THE EXPRESSION OF DISEASE RELATED GENES RIBOZYME PHARMACEUTICALS, INC. (US) 1995-08-31 WO disclosed